Measurable residual disease (MRD) is a key predictor of relapse, the primary cause of treatment failure after allogeneic haematopoietic cell transplantation (allo-HCT) in acute myeloid leukaemia. This Policy Review, based on guidance from the European Society for Blood and Marrow Transplantation, provides practical recommendations for incorporating MRD assessment into clinical decision making during the transplantation process, the application of which…
[Policy Review] Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee
The Lancet Oncology | | Jaime Sanz, Gesine Bug, Fabio Ciceri, Charles Craddock, Richard Dillon, Jordi Esteve, Matteo Giovanni Della Porta, Michael Heuser, David C de Leeuw, Arnon Nagler, Francesco Onida, Gail J Roboz, Annalisa Ruggeri, Isabel Sánchez-Ortega, Micha Srour, Ibrahim Yakoub-Agha, Francesco Buccisano
Topics: blood-cancer